Results 131 to 140 of about 2,101 (161)

Filgotinib for ulcerative colitis

Nature Reviews Gastroenterology & Hepatology, 2021
openaire   +2 more sources

Comparable Clinical Effectiveness of Baricitinib and Filgotinib in Patients With Rheumatoid Arthritis

International Journal of Rheumatic Diseases
ABSTRACTAimTo compare the clinical effectiveness of baricitinib and filgotinib in the treatment of rheumatoid arthritis (RA).MethodsThis retrospective study included 101 and 103 consecutive patients treated with baricitinib and filgotinib, respectively, between 2020 and 2023. Drug retention was analyzed using Kaplan–Meier curves, with the log‐rank test
Hironobu Kosugiyama, Shuji Asai, Kenya Terabe, Tomonori Kobayakawa, Yutaka Yoshioka, Tatsuo Watanabe, Toshihisa Kojima, Yasumori Sobue, Takefumi Kato, Takayoshi Fujibayashi, Yuji Hirano, Tsuyoshi Nishiume, Mihoko Kato, Yasuhide Kanayama, Toki Takemoto, Masahiro Hanabayashi, Hiroyuki Matsubara, Mochihito Suzuki, Ryo Sato, Junya Hasegawa, Yusuke Ohno, Takaya Sugiura, Nobunori Takahashi, Shiro Imagama   +23 more
openaire   +2 more sources

Filgotinib as induction and maintenance therapy for ulcerative colitis (SELECTION): a phase 2b/3 double-blind, randomised, placebo-controlled trial

Lancet, The, 2021
B G Feagan, Silvio Danese, Edward V Loftus   +2 more
exaly  

Filgotinib/prednisolone

Reactions Weekly, 2023
openaire   +1 more source

Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis

Journal of Crohn's and Colitis, 2022
Ferdinando D'Amico, Fernando Magro, Laurent Peyrin-Biroulet   +2 more
exaly  

Efficacy and safety of filgotinib in combination with methotrexate in Japanese patients with active rheumatoid arthritis who have an inadequate response to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 1)

Modern Rheumatology, 2022
Yoshiya Tanaka, Tsukasa Matsubara, Tatsuya Atsumi   +2 more
exaly  

Filgotinib decreases both vertebral body and posterolateral spine inflammation in ankylosing spondylitis: results from the TORTUGA trial

Rheumatology, 2022
Walter P Maksymowych, Mikkel Østergaard, Robert B M Landewé   +2 more
exaly  

Exposure‐response relationships for the efficacy and safety of filgotinib and its metabolite GS‐829845 in subjects with rheumatoid arthritis based on phase 2 and phase 3 studies

British Journal of Clinical Pharmacology, 2022
Amy Meng, Cara Nelson, Beatrix Bartok
exaly  

Efficacy and safety of filgotinib alone and in combination with methotrexate in Japanese patients with active rheumatoid arthritis and limited or no prior exposure to methotrexate: Subpopulation analyses of 24-week data of a global phase 3 study (FINCH 3)

Modern Rheumatology, 2022
Tatsuya Atsumi, Yoshiya Tanaka, Tsukasa Matsubara   +2 more
exaly  

Filgotinib, a JAK1 Inhibitor, Has No Effect on QT Interval in Healthy Subjects

Clinical Pharmacology in Drug Development, 2020
Florence Namour
exaly